Clinical trial / 2023
CurQfen-curcumin supplementation improved cognitive scores, locomotor function, and related biomarkers in subjects with moderate Alzheimer's dementia.
A 6-month randomized, double-blind, placebo-controlled study evaluated 48 subjects with moderate Alzheimer's disease dementia assigned to 400 mg twice daily of placebo, unformulated standard curcumin complex, or bioavailable CurQfen-curcumin (CGM). Supplementation with CGM led to significant improvements (P < 0.05) in Mini-Mental State Examination (MMSE) and Geriatric Locomotive Function Scale (GLFS) scores in both intra- and inter-group comparisons. Analysis of serum biomarkers (BDNF, Aβ42, tau protein, IL-6, and TNF-α) also demonstrated significant improvement (P < 0.05) in the CGM group compared to both placebo and unformulated curcumin.
- Study type
- Randomized, double-blind, placebo-controlled 3-arm comparative trial
- Who was studied
- 48 subjects with moderate dementia due to the onset of Alzheimer's disease
- What was measured
- Cognitive and locomotor function scores (MMSE, GLFS) and serum biomarkers (BDNF, Aβ42, tau protein, IL-6, TNF-α)
THE PAPER
Influence of CurQfen®-curcumin on cognitive impairment: a randomized, double-blinded, placebo-controlled, 3-arm, 3-sequence comparative study.
Das SS, Gopal PM, Thomas JV, Mohan MC, Thomas SC, Maliakel BP, Krishnakumar IM, Pulikkaparambil Sasidharan BC. Front Dement, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.